REDUCE LAP-HF RANDOMIZED TRIAL II: A study to evaluate the Corvia Medical, Inc. IASD® System II to REDUCE Elevated Left Atrial Pressure in Patients with Heart Failure
The REDUCE LAP-HF II study is
evaluating the IASD® System II,
a non-surgical, medical device
designed to improve quality
of life by potentially reducing
breathlessness and fatigue.
Basic eligibility criteria:
Please contact the study coordinator for additional eligibility information.
Key Inclusion Criteria include:
- Chronic symptomatic heart failure
- Ongoing stable Goal Directed Medical Therapy for Heart Failure Management
-Ejection Fraction greater than or equal to 40%
Primary disease category: Heart/Cardiovascular
Sponsor: Corvia Medical Inc
Projected enrollment dates: May 2017 to May 2020
Official study title: REDUCE LAP-HF RANDOMIZED TRIAL II: A study to evaluate the Corvia Medical, Inc. IASD® System II to REDUCE Elevated Left Atrial Pressure in Patients with Heart Failure
ClinicalTrials.gov page:
http://www.clinicaltrials.gov/show/NCT#03088033